Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Front Immunol ; 15: 1355824, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38799447

RESUMEN

Objectives: IL26 levels are elevated in the blood and synovial fluid of patients with inflammatory arthritis. IL26 can be produced by Th17 cells and locally within joints by tissue-resident cells. IL26 induces osteoblast mineralization in vitro. As osteoproliferation and Th17 cells are important factors in the pathogenesis of axial spondyloarthritis (axSpA), we aimed to clarify the cellular sources of IL26 in spondyloarthritis. Methods: Serum, peripheral blood mononuclear cells (n = 15-35) and synovial tissue (n = 3-9) of adult patients with axSpA, psoriatic arthritis (PsA) and rheumatoid arthritis (RA) and healthy controls (HCs, n = 5) were evaluated by ELISA, flow cytometry including PrimeFlow assay, immunohistochemistry and immunofluorescence and quantitative PCR. Results: Synovial tissue of axSpA patients shows significantly more IL26-positive cells than that of HCs (p < 0.01), but numbers are also elevated in PsA and RA patients. Immunofluorescence shows co-localization of IL26 with CD68, but not with CD3, SMA, CD163, cadherin-11, or CD90. IL26 is elevated in the serum of RA and PsA (but not axSpA) patients compared with HCs (p < 0.001 and p < 0.01). However, peripheral blood CD4+ T cells from axSpA and PsA patients show higher positivity for IL26 in the PrimeFlow assay compared with HCs. CD4+ memory T cells from axSpA patients produce more IL26 under Th17-favoring conditions (IL-1ß and IL-23) than cells from PsA and RA patients or HCs. Conclusion: IL26 production is increased in the synovial tissue of SpA and can be localized to CD68+ macrophage-like synoviocytes, whereas circulating IL26+ Th17 cells are only modestly enriched. Considering the osteoproliferative properties of IL26, this offers new therapeutic options independent of Th17 pathways.


Asunto(s)
Antígenos CD , Artritis Psoriásica , Interleucinas , Sinoviocitos , Humanos , Artritis Psoriásica/inmunología , Artritis Psoriásica/metabolismo , Sinoviocitos/metabolismo , Sinoviocitos/inmunología , Sinoviocitos/patología , Masculino , Adulto , Femenino , Antígenos CD/metabolismo , Interleucinas/metabolismo , Interleucinas/sangre , Persona de Mediana Edad , Antígenos de Diferenciación Mielomonocítica/metabolismo , Espondiloartritis Axial/inmunología , Células Th17/inmunología , Células Th17/metabolismo , Membrana Sinovial/inmunología , Membrana Sinovial/metabolismo , Membrana Sinovial/patología , Articulaciones/patología , Articulaciones/inmunología , Articulaciones/metabolismo , Artritis Reumatoide/inmunología , Artritis Reumatoide/metabolismo , Artritis Reumatoide/sangre , Artritis Reumatoide/patología
2.
Med Klin (Munich) ; 105(8): 578-81, 2010 Aug.
Artículo en Alemán | MEDLINE | ID: mdl-20824416

RESUMEN

Digital ulcers in systemic sclerosis are painful ischemic necrotic lesions of the acra. Optimal treatment consists of conventional wound management and medication: iloprost infusions promote primary healing of the ulcers, while the dual endothelin receptor antagonist bosentan is used for secondary prophylaxis of new ulcers. The described case illustrates the essential interdisciplinary collaboration for optimal management of these patients.


Asunto(s)
Síndrome CREST/diagnóstico , Conducta Cooperativa , Dedos , Dermatosis de la Mano/diagnóstico , Comunicación Interdisciplinaria , Esclerodermia Limitada/diagnóstico , Úlcera Cutánea/diagnóstico , Angiografía , Antihipertensivos/uso terapéutico , Brazo/irrigación sanguínea , Bosentán , Síndrome CREST/tratamiento farmacológico , Antagonistas de los Receptores de Endotelina , Resultado Fatal , Estudios de Seguimiento , Dermatosis de la Mano/tratamiento farmacológico , Humanos , Iloprost/uso terapéutico , Pierna/irrigación sanguínea , Masculino , Persona de Mediana Edad , Esclerodermia Limitada/tratamiento farmacológico , Úlcera Cutánea/tratamiento farmacológico , Sulfonamidas/uso terapéutico , Vasodilatadores/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA